Anticancer Effect of Gallic Acid on Acidity-Induced Invasion of MCF7 Breast Cancer Cells.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
16 Aug 2023
Historique:
received: 03 08 2023
revised: 14 08 2023
accepted: 15 08 2023
medline: 28 8 2023
pubmed: 26 8 2023
entrez: 26 8 2023
Statut: epublish

Résumé

The acidic tumor environment has emerged as a crucial factor influencing the metastatic potential of cancer. We investigated the effect of an acidic environment on the acquisition of metastatic properties in MCF7 breast cancer cells and explored the inhibitory effects of gallic acid. Prolonged exposure to acidic culture conditions (over 12 weeks at pH 6.4) induced the acquisition of migratory and invasive properties in MCF7 cells, accompanied by increased expression of Matrix Metalloproteinase 2 and 9 (MMP2 and MMP9, respectively), together with alterations in E-cadherin, vimentin, and epithelial-to-mesenchymal transition markers. Gallic acid effectively inhibited the survival of acidity-adapted MCF7 (MCF7-6.4/12w) cells at high concentrations (>30 μM) and reduced metastatic characteristics induced by acidic conditions at low concentration ranges (5-20 μM). Moreover, gallic acid suppressed the PI3K/Akt pathway and the nuclear accumulation of β-catenin, which were elevated in MCF7-6.4/12w cells. These findings highlight the potential of gallic acid as a promising therapeutic agent for metastatic traits in breast cancer cells under acidic conditions.

Identifiants

pubmed: 37630786
pii: nu15163596
doi: 10.3390/nu15163596
pmc: PMC10458441
pii:
doi:

Substances chimiques

Matrix Metalloproteinase 2 EC 3.4.24.24
Gallic Acid 632XD903SP
Phosphatidylinositol 3-Kinases EC 2.7.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : The Clinical Medicine Research Institute of the Chosun University Hospital
ID : 2019

Références

Front Pharmacol. 2021 Oct 06;12:708967
pubmed: 34690755
Oncol Rep. 2020 May;43(5):1705-1713
pubmed: 32323843
Oncotarget. 2017 May 16;8(20):33972-33989
pubmed: 28430641
Mol Biol Rep. 2020 Jun;47(6):4587-4629
pubmed: 32333246
Sci Rep. 2020 Dec 15;10(1):21959
pubmed: 33319820
J Food Drug Anal. 2018 Apr;26(2):620-627
pubmed: 29567231
Cancer Res. 2009 Mar 15;69(6):2260-8
pubmed: 19276390
Oncol Rep. 2014 Jul;32(1):355-61
pubmed: 24859325
Oncotarget. 2014 Dec 15;5(23):12070-82
pubmed: 25504433
Biomol Ther (Seoul). 2022 Mar 1;30(2):151-161
pubmed: 34261818
Cancer Lett. 2009 Dec 28;286(2):161-71
pubmed: 19589639
Cancer Metastasis Rev. 2019 Jun;38(1-2):179-188
pubmed: 30729352
Biomed Pharmacother. 2018 Sep;105:491-497
pubmed: 29883944
Clin Exp Metastasis. 2022 Feb;39(1):117-137
pubmed: 33950409
Oncol Rep. 2016 May;35(5):3075-83
pubmed: 26987028
Cancer Res. 2006 Sep 1;66(17):8319-26
pubmed: 16951136
Front Pharmacol. 2020 Aug 20;11:1222
pubmed: 32973496
Cancer Biother Radiopharm. 2017 Oct;32(8):297-301
pubmed: 29053417
J Exp Clin Cancer Res. 2017 Sep 19;36(1):130
pubmed: 28927426
BMC Cancer. 2010 Aug 10;10:414
pubmed: 20696077
Nat Rev Cancer. 2017 Oct;17(10):577-593
pubmed: 28912578
Oncogene. 2006 Apr 6;25(15):2273-84
pubmed: 16288205
Cancers (Basel). 2021 Apr 23;13(9):
pubmed: 33922795
Ecotoxicology. 2022 Apr;31(3):440-446
pubmed: 35113271
Environ Toxicol Pharmacol. 2013 May;35(3):473-85
pubmed: 23501608
Anticancer Res. 2015 Jun;35(6):3147-54
pubmed: 26026074
Melanoma Res. 2011 Aug;21(4):267-73
pubmed: 21734530
Anticancer Res. 2018 Apr;38(4):2057-2067
pubmed: 29599323
J Ethnopharmacol. 2023 Feb 10;302(Pt A):115885
pubmed: 36328204
Oncol Rep. 2016 Oct;36(4):2025-32
pubmed: 27498716
Korean J Physiol Pharmacol. 2018 Sep;22(5):513-523
pubmed: 30181698
J Orthop Translat. 2023 Jan 04;39:34-42
pubmed: 36636358
Breast. 2022 Dec;66:15-23
pubmed: 36084384
Br J Cancer. 1999 Jun;80(7):1005-11
pubmed: 10362108
Cancer. 2002 Sep 1;95(5):1113-9
pubmed: 12209698
J Agric Food Chem. 2009 Aug 26;57(16):7596-604
pubmed: 20349925
J Physiol. 2021 Mar;599(6):1745-1757
pubmed: 33347611
Adv Exp Med Biol. 2007;599:155-61
pubmed: 17727260
Chemotherapy. 2012;58(3):185-94
pubmed: 22739044

Auteurs

Ran Hong (R)

Department of Pathology, College of Medicine, Chosun University, Gwangju 61452, Republic of Korea.

Sung-Chul Lim (SC)

Department of Pathology, College of Medicine, Chosun University, Gwangju 61452, Republic of Korea.

Tae-Bum Lee (TB)

Division of Premedical Science, College of Medicine, Chosun University, Gwangju 61452, Republic of Korea.

Song-Iy Han (SI)

Division of Premedical Science, College of Medicine, Chosun University, Gwangju 61452, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH